This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Aubrey Milunsky, MD, DSc; Hershel Jick, MD; Susan S. Jick, MPH; Kenneth J. Rothman, DrPH; Walter Willett, MD
Boston (Mass) University School of Medicine

JAMA. 1990;263(20):2748-2749.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

First, there is substantial evidence in this population of women that there is little difference in the reported multivitamin (MV)/folate use when comparing women who were at low risk for an NTD baby with those who were at high risk. Among all women who had only a maternal serum -fetoprotein determination (low-risk women), 45% reported a history of MV/folate intake in the first 6 weeks of pregnancy, compared with 53% among those who had amniocentesis (high-risk women). Among study women with no family history of NTD (low risk), the use of MV/ folate in the first 6 weeks of pregnancy was 47%, compared with 48% among women with a family history of NTD (high risk). The results indicate that, if anything, high-risk women were slightly more likely to report MV/folate use than were low-risk women. If this were bias, it would be in the direction of elevating the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?